Innovative Technology Identifies Broad Range of Pathogens
|
By LabMedica International staff writers Posted on 23 Sep 2014 |
A platform has been developed with the goal to deliver a broad range of tests that can identify hundreds of bacteria, fungi, and viruses directly from a patient specimen within eight hours.
The pioneering testing technology could reduce hospital stays by up to eight days and lower annual health care costs for people with serious infections by approximately USD 2.2 million.
The cost reductions were based on a health economic model from the RApid Diagnosis of Infections in the CriticAlly IlL (RADICAL) study. An independent, expert panel of physicians reviewed the RADICAL study results from samples obtained from 420 critically ill patients with suspected severe infections from the United Kingdom, France, Belgium, Poland, Switzerland, and Germany.
The RADICAL study indicated that polymerase chain reaction/Electrospray Ionization Mass Spectrometry or PCR/ESI-MS (Abbott, Abbot Park, IL, USA) has the ability to detect the source of the infection such as bacteria, fungi, or viruses, within hours, even when blood cultures, the current standard of care, are negative. This information could help doctors diagnose and initiate appropriate treatments more quickly.
The platform known as IRIDICA currently differentiates between 600 bacterial families, as well as 200 families of fungi and 13 families of viruses. The PCR/ESI-MS technology may offer the potential for earlier discontinuation of broad-spectrum antibiotics. After retrospectively comparing Abbott's technology versus culture, the physicians reported they would have prescribed a different course of treatment in 57% of the cases evaluated based on the Abbott technology results.
Jean-Louis Vincent, MD, PhD, professor of Intensive Care at the Universite Libre de Bruxelles (Brussels, Belgium) said, “More than 50% of blood culture tests come back negative, even when infections are believed to exist. The results of the RADICAL study and the economic analysis suggest the Abbott technology will provide actionable information much earlier, allow physicians to improve patient outcomes and may ultimately lower overall health care costs related to these serious infections.” The IRIDICA platform is expected to be available as a Conformité Européenne (CE) marked in vitro diagnostic device in European countries within the coming months. The study was presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy held September 5-9, 2014, in Washington DC (USA).
Related Links:
Abbott
Universite Libre de Bruxelles
The pioneering testing technology could reduce hospital stays by up to eight days and lower annual health care costs for people with serious infections by approximately USD 2.2 million.
The cost reductions were based on a health economic model from the RApid Diagnosis of Infections in the CriticAlly IlL (RADICAL) study. An independent, expert panel of physicians reviewed the RADICAL study results from samples obtained from 420 critically ill patients with suspected severe infections from the United Kingdom, France, Belgium, Poland, Switzerland, and Germany.
The RADICAL study indicated that polymerase chain reaction/Electrospray Ionization Mass Spectrometry or PCR/ESI-MS (Abbott, Abbot Park, IL, USA) has the ability to detect the source of the infection such as bacteria, fungi, or viruses, within hours, even when blood cultures, the current standard of care, are negative. This information could help doctors diagnose and initiate appropriate treatments more quickly.
The platform known as IRIDICA currently differentiates between 600 bacterial families, as well as 200 families of fungi and 13 families of viruses. The PCR/ESI-MS technology may offer the potential for earlier discontinuation of broad-spectrum antibiotics. After retrospectively comparing Abbott's technology versus culture, the physicians reported they would have prescribed a different course of treatment in 57% of the cases evaluated based on the Abbott technology results.
Jean-Louis Vincent, MD, PhD, professor of Intensive Care at the Universite Libre de Bruxelles (Brussels, Belgium) said, “More than 50% of blood culture tests come back negative, even when infections are believed to exist. The results of the RADICAL study and the economic analysis suggest the Abbott technology will provide actionable information much earlier, allow physicians to improve patient outcomes and may ultimately lower overall health care costs related to these serious infections.” The IRIDICA platform is expected to be available as a Conformité Européenne (CE) marked in vitro diagnostic device in European countries within the coming months. The study was presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy held September 5-9, 2014, in Washington DC (USA).
Related Links:
Abbott
Universite Libre de Bruxelles
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Microbiology News
- New WHO Tools Address Gaps in Antimicrobial Resistance Testing
- Complete Malaria Genomes Could Improve Species Identification and Surveillance
- Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum
- Automated Microbial Identification and Susceptibility System Gains FDA Clearance
- Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
- Molecular Panels Gain FDA Clearance for One-Hour Gastrointestinal Pathogen Testing
- Common Genetic Variant Increases Risk of Bacterial Pneumonia
- Rapid Host-Response Assay Gains FDA Clearance to Help Distinguish Bacterial and Viral Infections
- Stool Testing Predicts UTI Risk and Guides Antibiotic Selection
- Repeat Prenatal STI Screening and Treatment May Reduce Preterm Births
- Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea
- Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
- Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis
- Oral and Lung Microbiome Changes Linked to Severe Long Covid Symptoms
- Study Finds Distinct Malaria Parasites Linked to Sickle Cell Trait Protection
- Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis
Channels
Clinical Chemistry
view channel
Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreMolecular Diagnostics
view channel
Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment
Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more
Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis
Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more
Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk
Breast cancer screening can reduce mortality, but early detection remains challenging when tumors are small or difficult to identify through imaging. Blood-based liquid biopsies offer a potential complementary... Read more
Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes
Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians
Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more








